v-2.jpg
logo-1-new.png

Media

Press Releases and Featured News

Blue Line.png

June 9, 2022 - Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis... read more

Blue Line.png

May 26, 2022 - Two years post-stealth exit, highly secretive inflammation biotech secures final tranche of Series A round... read more

Blue Line.png

May 25, 2022 - Amytrx Therapeutics Raises $18M for New AD Treatment... read more

Blue Line.png

October 21, 2021 - Amtryx Therapeutics is featured in Pharma's Almanac 'The Road to 50 States' Interviews... read more

Blue Line.png

June 8, 2021 - VUMC team develops potential treatment for life-threatening microbial inflammation...read more

Blue Line.png

October 27, 2020 - Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment...read more

Blue Line.png

October 19, 2020 - CEOCFO Magazine Interview with Amytrx CEO About Advancing the Next Generation of Inflammation-Targeting Therapies: AMTX-100 Technology delivers First-in-Class Biologically Active Molecule to Treat Chronic Diseases Mediated by Inflammation...read more

Blue Line.png

October 8, 2020 - Amytrx Enrolling Clinical Trial of AMTX-100 in Patients with Atopic Dermatitis...read more

Blue Line.png

September 17, 2020 - Amytrx Therapeutics Emerges from Stealth to Develop Novel Therapies for Inflammatory Diseases with Lead Program AMTX-100 Currently in Clinical Development for Dermatologic Indications....read more